Analyst consensus rating
MaxCyte Analyst Rating: Strong Buy
MXCT is rated Strong Buy by 4 analysts with a $4.11 target. As of 2026-08-17.
Direct answer
MaxCyte's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.11.
Forecast evidence checked August 17, 2026.
Get free MaxCyte email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.32
- Average price target
- $4.11
- High price target
- $5.00
- Low price target
- $2.43
- Low target gap
- +84.1%
- Target upside
- +211.2%
- High target gap
- +278.8%
- Target range width
- 194.7%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- August 17, 2026
- Valid through
- August 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for MaxCyte?
MaxCyte has a verified Strong Buy consensus. The same dataset has an average price target of $4.11.
How far are MaxCyte's low and high targets from the recorded price?
The low target implies +84.1%, while the high target implies +278.8%.
How many analysts are included in MaxCyte's consensus?
The verified consensus includes 4 analysts.
How is MaxCyte's target upside or downside calculated?
The average target of $4.11 is divided by the recorded price of $1.32, then one is subtracted to produce +211.2%. This does not guarantee a future return.
When was MaxCyte's analyst forecast verified?
The data was verified on 2026-08-17. The dataset is valid through 2026-08-24.